Chemotherapy-associated polyneuropathy: problems and objects at the current stage of neurological assistance to oncological patients


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Oncological diseases are the second most frequent cause of death both in the world and in Russia. Annually up to 14 million new cases of oncological diseases are registered in the world. The number of patients receiving chemotherapy increased significantly due to an increase in the survival period for breast cancer, colorectal cancer, bronchopulmonary cancer, bladder cancer, melanoma, leukemia, and non-Hodgkin’s lymphoma. Among patients receiving chemotherapeutic treatment, 30-40% will suffer from polyneuropathy of varying severity. Some patients will not be able to continue the main treatment due to the development of dose-limiting neurological complications. The problem of study of chemotherapy-induced polyneuropathy concerns all its aspects, including epidemiology, the phenomenology of standardization of approaches to prevention, effective treatment and specific approaches to rehabilitation, taking into account the main diagnosis. In the absence of neuroprotective therapy, particular attention should be paid to the timely diagnosis and adequate prevention of the development of polyneuropathy taking into account the individual patient characteristics. In the context of the accumulation of data on the safety of the use of certain physical and physiotherapeutic methods, the development of rehabilitation strategies, along with rational psychotherapy, is necessary to overcome the complications of life-saving treatment of the oncological process.

全文:

受限制的访问

作者简介

F. Abbasov

FSBI “State Scientific Center of the Russian Federation “Federal Medical Biophysical Center n.a. A.I. Burnazyan FMBA of Russia"

M. Anikina

FSBI “State Scientific Center of the Russian Federation “Federal Medical Biophysical Center n.a. A.I. Burnazyan FMBA of Russia"

O. Zimnyakova

FSBI “State Scientific Center of the Russian Federation “Federal Medical Biophysical Center n.a. A.I. Burnazyan FMBA of Russia"

A. Davtyan

FSBI “State Scientific Center of the Russian Federation “Federal Medical Biophysical Center n.a. A.I. Burnazyan FMBA of Russia"

E. Bril

FSBI “State Scientific Center of the Russian Federation “Federal Medical Biophysical Center n.a. A.I. Burnazyan FMBA of Russia"

Email: e.brill@inbox.ru
PhD, Associate Professor at the Department of Neurology FSBEI FPE RMACPE of RMH, Chief Neurologist of FMBA of Russia, Head of Federal Neurological Center

参考

  1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359-86.
  2. Cavaletti G., Marmiroli P. Chemotherapy-induced neurotoxicity Nat. Rev. Neurol. 2010;6(12):657-66.
  3. Grisold W., Cavaletti G., Windebank A.J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and preventbn. Neuro. Oncol. 2012;14(Suppl 4):iv45-54.
  4. Brzezinski К. Chemotherapy-induced polyneuropathy. Part I. Pathophysiology. Contemp. Oncol. (Pozn). 2012;16(1):72-8.
  5. Moghadamyeghaneh Z., Alizadeh R.F., Phelan M., Carmichael J.C., Mills S., Pigazzi A., Zell J.A., Stamos M.J. Trends in colorectal cancer admissions and stage at presentation: impact of screening. Surg. Endosc. 2016;30(8): 3604-10.
  6. Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-Induced Peripheral Neuropathy: A Current Review. Ann. Neurol. 2017;81(6):772-81.
  7. Briani C., Vitaliani R., Grisold W., Honnorat J., Graus F., Antoine J.C., Bertolini G., Giometto B.; PNS Euronetwork. Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011;76(8):705-10.
  8. Mendoza T.R., Wang X.S., Williams L.A., Shi Q., Vichaya E.G., Dougherty P.M., Thomas S.K., Yucel E., Bastida C.C., Woodruff J.F., Cleeland C.S. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale. J. Pain. 2015;16(10): 1032-43.
  9. Brzezinski К. Chemotherapy-induced peripheral neuropathy. Part II. Prevention. Contemp. Oncol. (Pozn). 2012;16(3):258-61.
  10. Cavaletti G., Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur. J. Cancer. 2002;38(14):1832-37.
  11. Холодова Н.Б., Сотников В.М., Добровольская Н.Ю., Особенности проявления и лечение постхимиотерапевтической полинейропатии. Вестник Российского научного центра рентгенорадиологии. 2010;10.
  12. Королева Е.С., Алифирова В.М., Гольдберг В.Е. и др. Клиническое, нейрофизиологическое и иммунологическое обследование пациентов с поражением периферических нервов, Бюллетень сибирской медицины. 2013;12(5):39-45.
  13. Королева Е.С., Алифирова В.М., Гольдберг В.Е. и др. Поражение периферических нервов паранеопластического и токсического генеза у пациентов, страдающих раком молочной железы и мелкоклеточным раком легкого. Неврологический журнал. 2013; 18(6):27-32.
  14. McKeage M.J. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13(4): 228-44.
  15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer. 2005;5(Suppl 1):S38-46.
  16. Postma T.J., Heimans J.J. Grading of chemotharapy-induced peripheral neuropathy. Ann. Oncol. 2000;11(5):509-13.
  17. Bakogeorgos M., Georgoulias V Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Expert Rev. Anticancer Ther. 2017;17(11):1045-60.
  18. Filipczak-Bryniarska I., Krzyzewski R.M., Kucharz J., Michalowska-Kaczmarczyk A., Kleja J., Woron J., Strzepek K., Kazior L., Wordliczek J., Grodzicki T., Krzemieniecki K. High-dose 8% capsaicin patch in treatment of chemotherapyinduced peripheral neuropathy: single-center experience. Med. Oncol. 2017;34(9):162.
  19. Carter G.T. Rehabilitation Management of Peripheral Neuropathy. Semin Neurol. 2005;25(2):229-37.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##